IL299506B2 - Tryptamine prodrugs - Google Patents

Tryptamine prodrugs

Info

Publication number
IL299506B2
IL299506B2 IL299506A IL29950622A IL299506B2 IL 299506 B2 IL299506 B2 IL 299506B2 IL 299506 A IL299506 A IL 299506A IL 29950622 A IL29950622 A IL 29950622A IL 299506 B2 IL299506 B2 IL 299506B2
Authority
IL
Israel
Prior art keywords
compound
alkyl
drug
depression
pct
Prior art date
Application number
IL299506A
Other languages
English (en)
Hebrew (he)
Other versions
IL299506A (en
IL299506B1 (en
Original Assignee
Reunion Neuroscience Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reunion Neuroscience Canada Inc filed Critical Reunion Neuroscience Canada Inc
Publication of IL299506A publication Critical patent/IL299506A/en
Publication of IL299506B1 publication Critical patent/IL299506B1/en
Publication of IL299506B2 publication Critical patent/IL299506B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL299506A 2020-06-30 2021-06-30 Tryptamine prodrugs IL299506B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063045901P 2020-06-30 2020-06-30
US202063109095P 2020-11-03 2020-11-03
PCT/CA2021/050907 WO2022000091A1 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs
US17/364,047 US11292765B2 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs

Publications (3)

Publication Number Publication Date
IL299506A IL299506A (en) 2023-02-01
IL299506B1 IL299506B1 (en) 2025-06-01
IL299506B2 true IL299506B2 (en) 2025-10-01

Family

ID=79032374

Family Applications (2)

Application Number Title Priority Date Filing Date
IL299506A IL299506B2 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs
IL320601A IL320601A (en) 2020-06-30 2025-04-30 Tryptamine prodrugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL320601A IL320601A (en) 2020-06-30 2025-04-30 Tryptamine prodrugs

Country Status (14)

Country Link
US (4) US11292765B2 (cg-RX-API-DMAC7.html)
EP (2) EP4172145B1 (cg-RX-API-DMAC7.html)
JP (2) JP7702654B2 (cg-RX-API-DMAC7.html)
KR (2) KR102829078B1 (cg-RX-API-DMAC7.html)
CN (3) CN119285527A (cg-RX-API-DMAC7.html)
AU (1) AU2021302692A1 (cg-RX-API-DMAC7.html)
CA (1) CA3181092A1 (cg-RX-API-DMAC7.html)
DK (1) DK4172145T3 (cg-RX-API-DMAC7.html)
FI (1) FI4172145T3 (cg-RX-API-DMAC7.html)
IL (2) IL299506B2 (cg-RX-API-DMAC7.html)
LT (1) LT4172145T (cg-RX-API-DMAC7.html)
MX (1) MX2022016212A (cg-RX-API-DMAC7.html)
PT (1) PT4172145T (cg-RX-API-DMAC7.html)
WO (1) WO2022000091A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス, インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
AU2021215709A1 (en) 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
DK4172145T3 (da) * 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
WO2022040802A1 (en) * 2020-08-26 2022-03-03 Magicmed Industries Inc. Glycosylated psilocybin derivatives and methods of using
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
JP2024500397A (ja) * 2020-12-18 2024-01-09 コンパス パスファインダー リミテッド 治療用途のための修飾インドールアルカロイド
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
EP4277894A1 (en) 2021-01-15 2023-11-22 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
JP2024520832A (ja) 2021-06-08 2024-05-24 エンセオジェニックス バイオサイエンシズ, インコーポレイテッド セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤
AU2022309017A1 (en) 2021-07-07 2024-01-25 Terran Biosciences Inc. N,n-dimethyltryptamine and related psychedlics and uses thereof
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
KR20240065084A (ko) * 2021-08-20 2024-05-14 테란 바이오사이언시스 인코포레이티드 사일로신의 전구약물 및 유도체 및 그의 용도
WO2023086962A1 (en) 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
AU2022408191B2 (en) * 2021-12-10 2025-05-15 Caamtech, Inc. Psilocybin derivatives
US20250051278A1 (en) * 2021-12-14 2025-02-13 Reunion Neuroscience, Inc. Tryptamine prodrugs
CA3242479A1 (en) 2021-12-27 2023-07-06 Atai Therapeutics, Inc. AMINOTERALINE SEROTONIN RECEPTOR ACTIVATORS
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023130075A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified organisms for producing psychotropic alkaloids
US20250066299A1 (en) * 2022-01-06 2025-02-27 Terran Biosciences Inc. Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20250186369A1 (en) * 2022-03-07 2025-06-12 Drexel University Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder
AU2023235712A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. C4-substituted tryptamine derivatives and methods of using
US12065404B2 (en) * 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493541A4 (en) * 2022-03-18 2026-02-25 Enveric Biosciences Canada Inc TRYPTAMINE DERIVATIVES SUBSTITUTED BY C4-CARBOXYLIC ACID AND METHODS OF USE
AU2022447256A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. C4-carbonothioate-substituted tryptamine derivatives and methods of using
AU2023254841B2 (en) * 2022-04-13 2025-10-23 Caamtech, Inc. Tryptamine derivatives
CN115521240B (zh) * 2022-06-01 2024-05-28 杭州奥泰生物技术股份有限公司 一种二甲基色胺半抗原和人工抗原及其制备方法与应用
AU2023313326A1 (en) * 2022-07-27 2024-12-19 Reconnect Labs Ag Highly soluble formulations of harmine
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
CN116283885B (zh) * 2022-12-01 2025-02-14 杭州奥泰生物技术股份有限公司 一种帕罗西汀半抗原和人工抗原及其制备方法与应用
WO2024145719A1 (en) * 2023-01-05 2024-07-11 Reunion Neuroscience Inc. Improved pharmacokinetics of tryptamine prodrugs
WO2024178051A2 (en) * 2023-02-22 2024-08-29 Caamtech, Inc. Tryptamine derivatives
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025099725A1 (en) * 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
WO2025238416A1 (en) * 2024-05-16 2025-11-20 Mindset Pharma Inc. Indole derivatives, uses and compositions thereof
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate
WO2026024591A1 (en) * 2024-07-22 2026-01-29 Reunion Neuroscience, Inc. Tryptamine prodrug solid forms
WO2026128398A1 (en) * 2024-12-09 2026-06-18 Reunion Neuroscience, Inc. Treatment of adjustment disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075992A (en) 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
NL121067C (cg-RX-API-DMAC7.html) 1958-09-12
CH373381A (de) 1959-07-13 1963-11-30 Sandoz Ag Verfahren zur Herstellung neuer basischer Indol-Derivate
CH386422A (de) 1960-03-30 1965-01-15 Sandoz Ag Verfahren zur Herstellung neuer Ester der Indol-Reihe
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
WO1995006638A1 (en) * 1993-09-01 1995-03-09 Allelix Biopharmaceuticals Inc. Tryptamine analogs with 5-ht1d selectivity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2006047032A2 (en) 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
US8809261B2 (en) 2008-10-31 2014-08-19 Elsohly Laboratories, Incorporated Compositions containing delta-9-THC-amino acid esters and process of preparation
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
DK4172145T3 (da) * 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
JP2024500397A (ja) * 2020-12-18 2024-01-09 コンパス パスファインダー リミテッド 治療用途のための修飾インドールアルカロイド

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAS RN 902412-24-2, CAS RN 902412-24-2, 17 August 2006 (2006-08-17) *

Also Published As

Publication number Publication date
KR102829078B1 (ko) 2025-07-04
IL320601A (en) 2025-07-01
CN115867533B (zh) 2024-07-23
EP4172145A1 (en) 2023-05-03
US20210403425A1 (en) 2021-12-30
JP7702654B2 (ja) 2025-07-04
IL299506A (en) 2023-02-01
IL299506B1 (en) 2025-06-01
EP4172145A4 (en) 2024-08-21
LT4172145T (lt) 2026-07-27
US20250129023A1 (en) 2025-04-24
CN115867533A (zh) 2023-03-28
MX2022016212A (es) 2023-03-02
KR20230028543A (ko) 2023-02-28
JP7864902B2 (ja) 2026-05-25
CN119285527A (zh) 2025-01-10
DK4172145T3 (da) 2026-07-20
US11292765B2 (en) 2022-04-05
EP4786000A2 (en) 2026-08-05
KR20250103811A (ko) 2025-07-07
FI4172145T3 (fi) 2026-07-22
JP2023531311A (ja) 2023-07-21
AU2021302692A1 (en) 2023-01-19
EP4172145B1 (en) 2026-05-13
PT4172145T (pt) 2026-07-17
US20250382267A1 (en) 2025-12-18
CN119285526A (zh) 2025-01-10
CA3181092A1 (en) 2022-01-06
WO2022000091A1 (en) 2022-01-06
US20220177427A1 (en) 2022-06-09
JP2025143280A (ja) 2025-10-01

Similar Documents

Publication Publication Date Title
IL299506B1 (en) Tryptamine prodrugs
US20250051278A1 (en) Tryptamine prodrugs
JP2008545663A (ja) タンパク質フォールディング障害の治療
CN103917093B (zh) 视蛋白结合配体、组合物及使用方法
IL297652B1 (en) Compositions containing methylphenidate prodrugs, processes for their preparation and use
AU2009200927A1 (en) Compositions and methods containing substituted quinolines and substituted diphenylsulfones
JP2002523367A (ja) カルバメートおよび尿素類組成物ならびに神経栄養剤としての使用
JP2021512958A (ja) 神経変性疾患を治療するための医薬及びその使用
HK40114605A (en) Tryptamine prodrugs
HK40114252A (en) Tryptamine prodrugs
HK40091294A (en) Tryptamine prodrugs
HK40091294B (en) Tryptamine prodrugs
HK40114112A (zh) 色胺前药
IL272366B (en) Adamantylmethylamine derivatives and their uses as a pharmaceutical preparation
JP2012524767A (ja) Ikk−bセリン・スレオニンプロテインキナーゼのチオフェン阻害剤
JPWO2011058943A1 (ja) Mchr1アンタゴニスト活性を有する化合物とnpyy5受容体アンタゴニスト活性を有する化合物を組み合わせてなる医薬組成物
Gordon-Blake Development of NAMPT Positive Allosteric Modulators as Potential Alzheimer’s Disease Therapeutics
US20240238249A1 (en) Lipidic Nano-Pharmaceuticals
IL323253A (en) Antidepressant compounds, pharmaceutical compositions and methods for treating depression and other disorders
JP2015166385A (ja) 疼痛および他の障害の処置のための化合物および方法